

# Apheresis

**Policy Number:** CS004.O  
**Effective Date:** March 1, 2023

[Instructions for Use](#)

Table of Contents	Page
<a href="#">Application</a> .....	1
<a href="#">Coverage Rationale</a> .....	1
<a href="#">Definitions</a> .....	4
<a href="#">Applicable Codes</a> .....	4
<a href="#">Description of Services</a> .....	5
<a href="#">Clinical Evidence</a> .....	6
<a href="#">U.S. Food and Drug Administration</a> .....	16
<a href="#">References</a> .....	17
<a href="#">Policy History/Revision Information</a> .....	19
<a href="#">Instructions for Use</a> .....	19

Related Community Plan Policy
<ul style="list-style-type: none"> <li><a href="#">Prolotherapy and Platelet Rich Plasma Therapies</a></li> </ul>
Commercial Policy
<ul style="list-style-type: none"> <li><a href="#">Apheresis</a></li> </ul>

## Application

This Medical Policy does not apply to the states listed below; refer to the state-specific policy/guideline, if noted:

State	Policy/Guideline
Indiana	None
Kentucky	<a href="#">Apheresis (for Kentucky Only)</a>
Louisiana	<a href="#">Apheresis (for Louisiana Only)</a>
New Jersey	<a href="#">Apheresis (for New Jersey Only)</a>
Ohio	<a href="#">Apheresis (for Ohio Only)</a>
Pennsylvania	<a href="#">Apheresis (for Pennsylvania Only)</a>
Tennessee	<a href="#">Apheresis (for Tennessee Only)</a>

## Coverage Rationale

**Therapeutic Apheresis** is proven and medically necessary for treating or managing the following conditions/diagnoses:

- Acute inflammatory demyelinating polyneuropathy (Guillain-Barré syndrome), primary treatment
- Acute liver failure [requiring [High Volume Therapeutic Plasma Exchange \(TPE-HV\)](#)]
- Anti-glomerular basement membrane disease (Goodpasture’s syndrome)
  - Dialysis independent
  - Diffuse alveolar hemorrhage (DAH)
- Chronic inflammatory demyelinating polyneuropathy (CIDP)
- Cryoglobulinemia, second line therapy
- Cutaneous T-cell lymphoma (CTCL); mycosis fungoides; Sézary syndrome, erythrodermic
- Dilated cardiomyopathy, idiopathic, New York Heart Association Class II-IV, via Immunoabsorption
- Familial hypercholesterolemia
  - Homozygous
  - Heterozygous, second line therapy

- Focal segmental glomerulosclerosis, recurrent in transplanted kidney, second line therapy
- Graft-versus-host disease
  - Acute
  - Chronic, second line therapy
- Hereditary hemochromatosis
- Hypertriglyceridemic pancreatitis, severe
- Hyperviscosity in hypergammaglobulinemia
- Inflammatory bowel disease, ulcerative colitis/Crohn's Disease via [Adsorptive Cytapheresis](#)
- Lipoprotein(a) hyperlipoproteinemia
- Multiple sclerosis, second line therapy
  - Acute central nervous system (CNS) inflammatory, demyelinating
  - Relapsing form with steroid resistant exacerbations
- Myasthenia gravis, acute
- Myeloma cast nephropathy, second line therapy
- Neuromyelitis optica spectrum disorders (NMOSD/Devic's syndrome), acute or relapse, second line therapy
- N-methyl D-aspartate receptor antibody encephalitis
- Paraproteinemic demyelinating neuropathies via Therapeutic Plasma Exchange (TPE)
  - Anti- myelin-associated glycoprotein (MAG)
  - Multifocal motor neuropathy
  - IgG/IgA
  - IgM
- Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) exacerbation
- Peripheral vascular diseases
- Polycythemia vera; erythrocytosis
- Progressive multifocal leukoencephalopathy (PML) associated with natalizumab
- Pruritus due to hepatobiliary diseases
- Rheumatoid arthritis, refractory, second line therapy
- Sickle cell disease
  - Acute stroke or multiorgan failure
  - Acute chest syndrome (ACS), severe, second line therapy
  - Stroke prevention
  - Individuals requiring chronic transfusion (receiving transfusions once every 5 weeks or more frequently)
- Thrombotic microangiopathy, thrombotic thrombocytopenic purpura (TTP)
- Transplantation, cardiac, second line therapy
  - Cellular/recurrent rejection
  - Desensitization
  - In children less than 40 months of age, ABO incompatible
- Transplantation, hematopoietic stem cell, ABO incompatible (ABOi), second line therapy
  - Haemopoietic progenitor cells collected from marrow HPC(M)
  - Haemopoietic progenitor cells collected by apheresis HPC(A)
- Transplantation, liver, desensitization, ABOi living donor
- Transplantation, lung, bronchiolitis obliterans syndrome
- Transplantation, renal, ABO compatible:
  - Antibody mediated rejection
  - Desensitization, living donor
- Transplantation, renal, ABO incompatible, second line therapy
  - Antibody mediated rejection
- Vasculitis, Antineutrophil cytoplasmic antibodies (**ANCA**)-associated
  - Dialysis dependent
  - DAH
- Vasculitis
  - Behcet's disease (Adsorptive Cytapheresis)
  - Idiopathic polyarteritis nodosa (PAN) (TPE)
- Voltage gated potassium channel (VGKC) antibody-related diseases
- Wilson's disease, fulminant

Due to insufficient evidence of efficacy, [Therapeutic Apheresis](#) including [Plasma Exchange](#), [Plasmapheresis](#), or [Photopheresis](#) is unproven and not medically necessary for treating or managing the following conditions/diagnoses, including but not limited to:

- Acute disseminated encephalomyelitis (ADEM)
- Acute liver failure (requiring TPE)
- Age related macular degeneration, dry
- Amyloidosis, systemic
- Amyotrophic lateral sclerosis
- ANCA-associated rapidly progressive glomerulonephritis, dialysis independent (Granulomatosis with polyangiitis; and Microscopic Polyangiitis)
- Anti-glomerular basement membrane disease, dialysis dependent, without DAH (Goodpasture's syndrome)
- Aplastic anemia; pure red cell aplasia
- Atopic (neuro-) dermatitis (atopic eczema), recalcitrant
- Autoimmune hemolytic anemia; severe warm autoimmune hemolytic anemia (WAIHA); severe cold agglutinin disease
- Babesiosis, severe
- Burn shock resuscitation
- Cardiac neonatal lupus
- Catastrophic antiphospholipid syndrome/Hemolytic uremic syndrome
- Chronic focal encephalitis (Rasmussen's encephalitis)
- Coagulation factor inhibitors
- Complex regional pain syndrome
- Cutaneous T-cell lymphoma; mycosis fungoides; Sézary syndrome, non-erythrodermic
- Dilated cardiomyopathy, idiopathic, New York Heart Association Class II-IV, via TPE
- Erythropoietic porphyria, liver disease
- Focal segmental glomerulosclerosis, recurrent kidney transplant or steroid resistant in native kidney via LA or TPE
- Hemolysis, Elevated Liver enzymes and Low Platelets (HELLP) syndrome
- Hemophagocytic lymphohistiocytosis (HLH) / Hemophagocytic syndrome / Macrophage activating syndrome
- Heparin induced thrombocytopenia and thrombosis (HIT/HITT)
- Hyperleukocytosis
- Hypertriglyceridemic pancreatitis, prevention of relapse
- Immune thrombocytopenia
- IgA nephropathy (Berger's Disease)
- Inflammatory bowel disease, Crohn's Disease, via Extracorporeal Photopheresis
- Lambert-Eaton myasthenic syndrome
- Malaria
- Multiple sclerosis, chronic
- Myasthenia Gravis, long term treatment
- Myeloma cast nephropathy
- Nephrogenic systemic fibrosis
- Neuromyelitis optica spectrum disorders (NMOSD), maintenance
- Overdose, envenomation, and poisoning
- Paraneoplastic neurologic syndromes
- Paraproteinemic demyelinating polyneuropathies, multiple myeloma (2C)
- Pemphigus vulgaris
- Phytanic acid storage disease (Refsum's disease)
- Post transfusion purpura (PTP)
- Psoriasis
- Red cell alloimmunization, prevention and treatment
- Scleroderma (systemic sclerosis)
- Sepsis with multiorgan failure
- Sickle cell disease (unless noted above as proven)
- Steroid-responsive encephalopathy associated with autoimmune thyroiditis (Hashimoto's encephalopathy)
- Stiff-person syndrome
- Sudden sensorineural hearing loss
- Sydenham's chorea, severe

- Systemic lupus erythematosus, severe complications
- Thrombocytosis
- Thrombotic microangiopathy
  - Coagulation mediated (THBD, DGKE and PLG mutations)
  - Complement mediated (Factor H autoantibody and complement factor gene mutations)
  - Drug associated
  - Infection associated (STEC-HUS, severe; pHUS)
  - Transplantation associated
- Thyroid storm
- Toxic epidermal necrolysis (TEN)
- Transplantation, cardiac
  - Rejection prophylaxis
  - Antibody mediated rejection
- Transplantation, hematopoietic stem cell ABOi:
  - HLA desensitized
  - Minor ABOi HPC(A)
  - Major/minor ABOi w/ pure RBC aplasia
- Transplantation, hematopoietic stem cell, HLA desensitization
- Transplantation, liver
  - ABO incompatible
  - Antibody mediated rejection
- Transplantation, lung
  - Antibody mediated rejection
  - Desensitization
- Transplantation, renal, ABO compatible, desensitization, deceased donor
- Vasculitis, ANCA-associated (AAV)
  - MPA/GPA/RLV: RPGN, Cr < 5.7
  - EGPA
- Vasculitis, IgA (Henoch-Schönlein purpura)
- Vasculitis (unless noted above as proven)

**Note:** Refer to the [Description of Services](#) section for information regarding all apheresis-based procedures.

## Definitions

**Photopheresis:** A procedure where blood is removed from the body, treated with ultraviolet light and medications that are activated by the ultraviolet light, then reinfused into the body (National Cancer Institute, 2021).

**Plasma Exchange:** A procedure that involves the use of a machine to separate and remove the plasma from the blood cells and then replace the plasma with a solution prior to reinfusion into the patient. Also called Plasmapheresis (National Cancer Institute, 2021).

**Therapeutic Apheresis:** A procedure in which blood is collected, part of the blood (such as platelets or white blood cells) are removed, and the remaining components of the blood are reinfused into the body. It is a general term which includes all apheresis-based procedures; also called pheresis (National Cancer Institute, 2021, Schwartz, et al., 2016, Padmanabhan, et al., 2019).

## Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by federal, state, or contractual requirements and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

CPT Code	Description
0342T	Therapeutic apheresis with selective HDL delipidation and plasma reinfusion
36511	Therapeutic apheresis; for white blood cells
36512	Therapeutic apheresis; for red blood cells
36513	Therapeutic apheresis; for platelets
36514	Therapeutic apheresis; for plasma pheresis
36516	Therapeutic apheresis; with extracorporeal immunoadsorption, selective adsorption or selective filtration and plasma reinfusion
36522	Photopheresis, extracorporeal

*CPT® is a registered trademark of the American Medical Association*

HCPCS Code	Description
S2120	Low density lipoprotein (LDL) apheresis using heparin-induced extracorporeal LDL precipitation

## Description of Services

Therapeutic apheresis does not include stem cell collection or harvesting for use in bone marrow/stem cell transplantation. It is usually performed in an outpatient facility and usually requires several hours to complete. In some clinical situations, plasma exchange may be performed daily for at least 1 week.

**Adsorptive Cytapheresis:** A therapeutic procedure in which blood of the patient is passed through a medical device, which contains a column or a filter that selectively adsorbs activated monocytes and granulocytes, allowing the remaining leukocytes and other blood components to be returned to the patient.

**B2 Microglobulin Column:** The B2 microglobulin apheresis column contains porous cellulose beads specifically designed to bind to B2 microglobulin as the patient's blood passes over the beads.

**Erythrocytapheresis:** A procedure in which blood of the patient or donor is passed through a medical device which separates red blood cells from other components of blood. The red blood cells are removed and replaced with crystalloid or colloid solution, when necessary.

**Extracorporeal Photopheresis (ECP):** A therapeutic procedure, in which the buffy coat is separated from the patient's blood, treated extracorporeally with a photoactive compound (e.g., psoralens) and exposed to ultraviolet A light then subsequently reinfused to the patient during the same procedure.

**Filtration Selective Removal:** A procedure which uses a filter to remove components from the blood based on size. Depending on the pore size of the filters used, different components can be removed. Filtration-based instruments can be used to perform plasma exchange or LDL apheresis. They can also be used to perform donor plasmapheresis where plasma is collected for transfusion or further manufacture.

**High-Volume Plasma Exchange (HVP):** HVP is defined as an exchange of 15% of ideal body weight (representing 8-12 L); patient plasma was removed at a rate of 1-2 L per hour with replacement with plasma in equivalent volume.

**Immunoadsorption (IA):** A therapeutic procedure in which plasma of the patient, after separation from the blood, is passed through a medical device which has the capacity to remove immunoglobulins by specifically binding them to the active component (e.g., Staphylococcal protein A) of the device.

**Low-Density Lipoprotein (LDL) Apheresis:** The selective removal of low-density lipoproteins from the blood with the return of the remaining components. A variety of instruments are available which remove LDL cholesterol based on charge (dextran sulfate and polyacrylate), size (double-membrane filtration), precipitation at low pH (HELP), or immunoadsorption with anti-Apo B-100 antibodies.

**Leukocytapheresis (LCP):** A procedure in which blood of the patient or the donor is passed through a medical device which separates white blood cells (e.g., leukemic blasts or granulocytes), collects the selected cells, and returns the remainder of the patient's or the donor's blood with or without the addition of replacement fluid such as colloid and/or crystalloid solution. This procedure can be used therapeutically or in the preparation of blood components.

**Platelet Apheresis:** A procedure in which blood of the donor is passed through a medical device which separates platelets, collects the platelets, and returns the remainder of the donor's blood. This procedure is used in the preparation of blood components (e.g., apheresis platelets).

**Red Blood Cell (RBC) Exchange:** A therapeutic procedure in which blood of the patient is passed through a medical device which separates red blood cells from other components of blood. The patient's red blood cells are removed and replaced with donor red blood cells and colloid solution.

**Rheopheresis:** A therapeutic procedure in which blood of the patient is passed through a medical device which separates high-molecular-weight plasma components such as fibrinogen,  $\alpha$ 2-macroglobulin, low-density lipoprotein cholesterol, and IgM to reduce plasma viscosity and red cell aggregation. This is done to improve blood flow and tissue oxygenation. LDL apheresis devices and selective filtration devices using two filters, one to separate plasma from cells and a second to separate the high-molecular-weight components, are used for these procedures.

**Thrombocytapheresis:** A therapeutic procedure in which blood of the patient is passed through a medical device which separates platelets, removes the platelets, and returns the remainder of the patient's blood with or without the addition of replacement fluid such as colloid and/or crystalloid solution.

## Clinical Evidence

### Sickle Cell Disease

Red blood cell exchange or erythrocytapheresis is being increasingly used for transfusion therapy in sickle cell disease (SCD). Many of the studies performed to evaluate this therapy are retrospective studies with small patient population.

Wade et al. (2022) performed a retrospective review of pediatric sickle cell disease (SCD) patients receiving chronic red cell exchange (RCE) over 3 years to determine the frequency of adverse events (AEs) and identify procedural and patient AE risk factors. AE incidence, AE rate, incident rate ratios (IRRs), and relative risks (RR) were calculated based on various procedural and patient characteristics by univariable (UV) and multivariable (MV) analyses. In 38 patients receiving 760 procedures, there were 150 (19.7%) AEs, of which 36 (4.7%) were symptomatic AEs. The rate of AEs was 20.2 per 100 person-months (95% CI 17.2, 23.6), and the rate of symptomatic AEs was 4.8 per 100 person-months (95% CI 3.49, 6.70). AE incidences were hypocalcemia (117; 15.4%), dizziness (22; 3.0%), hypotension (15; 2.0%), and nausea (14; 1.8%). Patients with a baseline Hct  $\geq$  30% experienced more total AEs and symptomatic AEs. Pre-procedure initial systolic BP  $<$  50<sup>th</sup> percentile and patients with severe CNS vasculopathy and non SCA phenotype (i.e., HbSC or S $\beta$ + thalassemia) were associated with an increase in total AEs. IHD depletion was not associated with an increased incidence of AEs or symptomatic AEs. The authors concluded that SCD patients with HCT  $\geq$  30%, systolic BP  $<$  50<sup>th</sup> percentile, severe CNS vasculopathy and possibly non-SCA genotype may be at higher risk for RCE-related AEs. The effect of isovolemic hemodilution (IHD) on AE risk is likely minimal. Individualized AE risk assessment should be performed in all SCD patients undergoing chronic automated RCE.

A systematic review and meta-analysis by Mukherjee et al. (2022) was performed to evaluate the efficacy and safety profile of automated red cell exchange (aRBX) procedure over manual red cell exchange transfusion (MET) in sickle cell disease (SCD) patients. A standard meta-analysis protocol was developed, and after performing a comprehensive literature search in PubMed/MEDLINE, Cochrane and International Clinical Trial Registry Platform (ICTRP), reviewers assessed eligibility and extracted data from nine relevant studies. A random effects model was used to estimate the pooled effect size calculated from the mean difference in hemoglobin S (HbS) percentage, serum ferritin level and risk ratio for the adverse events. Quality assessment was done using the risk-of-bias assessment tool, and a summary of observations was prepared using standard Cochrane methodology with GradePro GDT. The random-model analysis revealed a mean difference of 4.10 (95% CI: -3.29-11.49; Z = 1.09; p = 0.28) for HbS percentage, mean difference of 435.29 (95% CI: -73.74-944.32; Z = 1.68; p = 0.09) for serum ferritin and pooled risk ratio of 1.35 (95% CI: 0.63-2.87; Z = 0.77; p = 0.44) for adverse events. The authors concluded that this



meta-analysis did not reveal any benefit of aRBX in reducing HbS percentage and attenuating the serum ferritin level when compared with MET. There was also no significant increased risk of adverse events detected in association with aRBX.

Hequet et al. (2021) completed a prospective analysis to evaluate the clinical safety of the red blood cell (RBC) exchange (RCE)/RBC-primed procedure in 12 sickle cell anemia (SCA) low-weight children under either a chronic RCE program or emergency treatment over 65 sessions. The authors monitored grade 2 adverse events (AEs) such as a decrease in blood pressure, increase in heart rate, fainting sensation, or transfusion reactions and identified the critical times during the sessions in which adverse events (AEs) could occur. Post-apheresis hematocrit (Hct) and a fraction of cell remaining (FCR) values were compared to the expected values. We also compared the impact of automatic RCE (n = 7) vs. RCE/RBC-primed (n = 8) on blood viscosity and RBC rheology. A low incidence of complications was observed in the 65 RCE sessions with only seven episodes of transient grade 2 AEs. Post-apheresis Hct and FCR reached expected values with the RCE/RBC-primed method. Both the automatic and priming procedures improved RBC deformability and decreased the sickling tendency during deoxygenation. Blood rheological features improved in both RCE/RBC-primed and automatic RCE without priming conditions. The authors concluded that RCE/RBC-primed procedure provides blood rheological benefits, and is safe and efficient to treat, notably in young children with SCA in prophylactic programs or curatively when a SCA complication occurs.

Cochrane has published systematic reviews for the use of transfusion therapies, including simple or exchange transfusions, for the treatment of complications of sickle cell disease including chronic chest complications (Estcourt et al, 2019) and intrahepatic cholestasis (Martí-Carvajal and Martí-Amarista, 2020). In both of these systematic reviews, the authors could not find any published randomized controlled trials to evaluate the use of transfusion therapies in these instances. The authors recommend randomized controlled trials looking at the safety and efficacy of transfusion therapies compared to current standard therapies for these complications of sickle cell disease.

Wahl et al. (2012) compared alloimmunization rates between patients receiving simple or exchange chronic transfusions with erythrocytapheresis (ECP). Data were retrospectively collected for 45 SCD patients (n = 23 simple, n = 22 ECP) who received blood transfusion of 10 to 15 ml of red blood cells (RBCs)/kg with each transfusion every 3 to 4 weeks on a chronic transfusion program to determine the rate of antibody formation (antibodies formed per 100 units transfused). The 45 patients received 10,949 units and formed six new alloantibodies during the study period; therefore, the overall alloimmunization rate was 0.055 alloantibodies per 100U. The ECP group received significantly more blood. The rate of antibody formation (auto plus allo) was 0.040 antibodies per 100U in the ECP group and 0.171 antibodies per 100U in the simple transfusion group. The alloantibodies formed per 100 units was 0.013 in the ECP group and 0.143 in the simple transfusion group. The authors concluded that chronic ECP should be considered in patients requiring optimal management of HbS levels and iron burden. The authors stated that concerns about increased alloimmunization with ECP may be unjustified.

In a single center retrospective case series, Venkateswaran et al. (2011) performed chart reviews on 93 patients to evaluate the incidence of allo- and auto-immunization to red cell antibodies in patients with sickle cell disease (SCD) who were started on chronic red cell transfusion (RCT). Each patient received RCTs every 3-4 weeks for a minimum of 6 months with a total of 4,472 packed red blood cell units being administered. The authors reported that nine patients (9%) had red cell antibodies prior to the initiation of chronic RCT and 23 patients (24%) developed one or more red cell antibodies during chronic RCT. The authors concluded that limited red cell antigen matching is effective for reducing the incidence of allo- and auto-immunization in chronically transfused children with SCD and that RCE does not appear to increase the risk of allo- or auto-immunization, despite exposure to more red cell units.

Velasquez et al. (2009) retrospectively reviewed red cell exchange (RCE) for the management of acute chest syndrome (ACS) in 44 patients with SCD. Clinical Respiratory Score (CRS) was assigned retrospectively to assess respiratory distress (0 = no distress, > 6 = severe). Median admission CRS of 2, progressed to 4 before RCE and declined to 2 within 24 hr. afterwards. Median day of RCE was day 2 (IQR 1-3) and the main indication was worsening respiratory distress. No patient developed venous thrombosis, alloantibodies or other complications from RCE. According to the authors, RCE appears to be a safe and effective treatment for patients with SCD and ACS. The small study population limits the validity of the conclusion of this study.

Turner et al. (2009) evaluated the efficacy of exchange transfusion (XC) versus simple transfusion (ST) for treatment of SCA ACS. Twenty patients who received XC for ACS were compared with 20 patients who received ST. Cohorts were similar with regard to age; sex; prior ACS episodes; echocardiogram results; and antibiotic, bronchodilator, and hydroxyurea use. Maximum temperature recorded was higher in the XC group, but lactate dehydrogenase (LDH), WBCs, and indirect bilirubin were comparable. Admission Hb levels were higher for XC (XC 8.6 g/dL vs. ST 7.4 g/dL, p = 0.02) and XC had higher peak Hb

levels during hospitalization. No differences were demonstrable in post-procedure length of stay (XC 5.6 days vs. ST 5.9 days) or total length of stay (XC 8.4 days vs. ST 8.0 days). A total of  $10.3 \pm 3.0$  units were transfused for XC compared to  $2.4 \pm 1.2$  units for ST. Based on post-procedure length of stay or total length of stay, the authors could not detect a difference in the efficacy of XC compared to ST in populations despite red blood cell product usage fourfold higher in the XC group. According to the authors, there is a need for an adequately powered, randomized trial to examine the true risk-benefit ratio of XC in ACS.

Hulbert et al. (2006) conducted a retrospective cohort study of 137 children with sickle cell anemia (SCA) and strokes to test the hypothesis that exchange transfusion at the time of stroke presentation more effectively prevents second strokes than simple transfusion. Children receiving simple transfusion had a 5-fold greater relative risk of second stroke than those receiving exchange transfusions. Interpretation of these findings is limited due to the retrospective design of the study.

## Desensitization for Renal Transplants

Plasmapheresis has been used prior to renal transplants in highly sensitized patients to remove human leukocyte antigen (HLA) antibodies. Desensitization protocols use high dose intravenous immunoglobulin (IVIG) or low dose IVIG with plasmapheresis to convert a positive crossmatch to a negative crossmatch and allow for transplantation. Plasmapheresis may continue after the transplant or be reserved for posttransplant treatment of acute antibody mediated rejection (AMR). Clinical trials have demonstrated that living or deceased donor kidney recipients treated with plasmapheresis and IVIG have beneficial outcomes.

In a single-center retrospective study, Campise et al (2019) evaluated their experience with prophylactic and therapeutic plasmapheresis in a cohort of 21 deceased-donor kidney transplant recipients with primary focal segmental glomerulosclerosis (FSGS). The analyzed ten patients who received post-transplant prophylactic plasmapheresis only with eleven who received both pre- and post-transplant prophylactic plasmapheresis. They also compared these groups to a historical control group of transplant recipients with FSGS who did not receive plasmapheresis prophylaxis. The authors observed that response to treatment was only seen in patients who received a more intensive prophylactic plasmapheresis regimen and that half of the recipients with FSGS recurrence did not respond to plasmapheresis and developed graft failure, a quarter of the recipients showed complete response and the remaining 25% became plasmapheresis dependent. While therapeutic plasmapheresis is still a valid treatment option for first-line treatment of relapsing FSGS, the authors concluded that there is no benefit from prophylactic plasmapheresis in deceased-donor kidney transplant recipients with FSGS and recommended that prospective randomized trials comparing alternative preemptive strategies be done. They acknowledged the limitations of this study including the retrospective view, the small, homogeneous sample size, and the differences in follow-up between the treatment groups.

Montgomery et al. (2011b) used mathematical simulations verified by actual data from several national kidney-paired donation (KPD) programs to evaluate which donor/recipient phenotypes are likely to benefit from each transplant modality. They found that pairs that are easy to match are likely to receive compatible kidneys in a KPD. Those who are hard to match may be better served by desensitization with high-dose IVIG or plasmapheresis and low-dose IVIG. The phenotype which is both hard to match and hard to desensitize due to board and strong HLA reactivity are most likely to be transplanted by a hybrid modality utilizing desensitization after identifying a more immunologically favorable donor in a KPD. The authors state that recent outcomes from desensitization in which starting donor-specific antibody strength is low have been very good. For broadly sensitized patients with a high-strength cross match, searching for a better donor in a KPD pool can facilitate a safer and more successful desensitization treatment course.

Montgomery et al. (2011a) used a protocol that included plasmapheresis and the administration of low-dose IVIG to desensitize 211 human leukocyte antigen (HLA)-sensitized patients who underwent live-donor renal transplantation (treatment group). The rates of death were compared between the group undergoing desensitization treatment and two carefully matched control groups of patients on a waiting list for kidney transplantation who continued to undergo dialysis (dialysis-only group) or who underwent either dialysis or HLA-compatible transplantation (dialysis-or-transplantation group). In the treatment group, Kaplan-Meier estimates of patient survival were 90.6% at 1 year, 85.7% at 3 years, 80.6% at 5 years, and 80.6% at 8 years, as compared with rates of 91.1%, 67.2%, 51.5%, and 30.5%, respectively, for patients in the dialysis-only group and rates of 93.1%, 77.0%, 65.6%, and 49.1%, respectively, for patients in the dialysis-or-transplantation group. The authors concluded that live-donor transplantation after desensitization provided a significant survival benefit for patients with HLA sensitization, as compared with waiting for a compatible organ. By 8 years, this survival advantage more than doubled. According to the authors, plasmapheresis does not result in a durable reduction in HLA antibody unless the patient undergoes transplantation within several days after the last treatment. This factor accounts for the paucity of reports of protocols that use plasmapheresis to desensitize patients who are on the waiting list for a transplant from a deceased donor.



Yuan et al. (2010) evaluated the efficacy of plasmapheresis plus low-dose IVIG in highly sensitized patients waiting for a deceased-donor renal transplant. Thirty-five highly sensitized patients (HLA class I panel reactive antibody greater than 50%) received plasmapheresis, plus low-dose IVIG treatment. In 25 patients (group 1), a positive T- and/or B-cell cytotoxicity crossmatch became negative by plasmapheresis plus low-dose IVIG treatment. Two patients did not receive renal transplants due to persistent positive crossmatch. Eight patients already had a negative crossmatch before desensitization. During the same time, 32 highly sensitized patients (group 2), without desensitization, had a negative crossmatch and received deceased-donor renal transplants. Group 1 showed a numerically higher rate of acute rejection (32.0% vs. 21.9%) and AMR (20.0% vs. 9.4%), but the difference was not statistically significant. Comparable mean serum creatinine levels at 24 months were observed. No difference in Kaplan-Meier graft survival was found between group 1 and group 2 after follow-up of 52 ±26 months. The authors concluded that desensitization with plasmapheresis plus low-dose IVIG enables successful deceased-donor renal transplant in highly sensitized patients with a positive crossmatch. AMR occurred predominantly in recipients with donor-specific antibodies of high titers.

Meng et al. (2009) determined the percentage of panel reactivity and specificity of anti-HLA immunoglobulin (IgG) antibodies in 73 presensitized renal allograft recipients who underwent cadaveric renal transplantation compared with 81 unsensitized recipients who received cadaveric renal transplantation (control group). Sensitized patients had higher rates of graft rejection and graft loss. A total of 20 out of the 73 patients received pre-transplantation plasmapheresis (PP) and/or immunoadsorption (IA) and of these, 10 achieved negative panel reactive antibodies (PRAs). Graft rejection rate was 18% in the unsensitized group, 41% in the non-PP and/or IA sensitized group, and 20% in the PP and/or IA sensitized group. Graft loss rate was 5% in the unsensitized group, 21% in the non-PP and/or IA sensitized group, and 15% in the PP and/or IA sensitized group (20% positive PRA at transplant and 10% negative PRA at transplant). The authors concluded that pre-transplant PRA preparations might improve the access of presensitized patients to renal donors.

## **Pediatric ABO-Incompatible Heart Transplantation**

Issitt et al. (2021) completed a retrospective analysis and first case series of patients transplanted with ABO-IA to compare outcomes with those undergoing plasma exchange facilitated ABO-incompatible heart transplantation (ABO-PE). Data were retrospectively analyzed on all ABO-incompatible heart transplants undertaken at a single center between January 1, 2000, and June 1, 2020. Data included all routine laboratory tests, demographics and pre-operative characteristics, intraoperative details and post-operative outcomes. Primary outcome measures were volume of blood product transfusions, maximum post-transplant isohemagglutinin titers, occurrence of rejection, and graft survival. Secondary outcome measures were length of intensive care and hospital stay. Demographic and survival data were also obtained for ABO-compatible transplants during the same time period for comparison. Thirty-seven patients ages 7 months to 8 years old underwent ABO-incompatible heart transplantation, with 27 (73%) using ABO-PE and 10 (27%) using ABO-IA. ABO-IA patients were significantly older than ABO-PE patients ( $p < 0.001$ ) and the total volume of blood products transfused during the hospital admission was significantly lower [164 (126-212) ml/kg vs. 323 (268-379) ml/kg,  $p < 0.001$ ]. No significant differences were noted between methods in either pre- or post-transplant maximum isohemagglutinin titers, incidence of rejection, length of intensive care or total hospital stay. Survival comparison showed no significant difference between antibody reduction methods, or indeed ABO-compatible transplants ( $p = 0.6$ ). The authors concluded that this technique appears to allow a significantly older population than typical to undergo ABO-incompatible heart transplantation, as well as significantly reducing blood product utilization. Furthermore, intraoperative anti-A/B immunoadsorption does not demonstrate increased early post-transplant isohemagglutinin accumulation or rates of rejection compared to ABO-PE. Early survival is equivalent between ABO-IA, ABO-PE and ABO-compatible heart transplantation.

Issitt et al. (2012) performed a retrospective analysis of all elective ABO-incompatible heart transplants performed at a single center from January 2001 - January 2011. Data included underlying conditions and demographics of the patients, the isohemagglutinin titer before and after plasma exchange, and survival figures to date. Twenty-one patients (ages 3-44 months) underwent ABO-incompatible heart transplantation. All patients underwent a “3 times” plasma exchange before transplantation, requiring exchange volumes of up to 3,209 mL. Isohemagglutinin titers that were as high as 1:32 preoperatively were reduced to a range of 0-1:16 post transplantation. One patient expired from causes unrelated to organ rejection. The authors concluded that through the use of a combination of adult reservoir/pediatric oxygenator and extracorporeal circuit, ABO-incompatible plasma exchange transfusions can be undertaken safely using a simplified “3 times” method, reducing the circulating levels of isohemagglutinins while providing minimal circuit size. This allows ABO-incompatible heart transplantation in a broader patient population than reported previously.

Dipschand et al. (2010) conducted a non-randomized prospective observational single institution study comparing clinical outcomes over 10 years of the largest cohort of ABO-incompatible recipients. ABO-incompatible (n = 35) and ABO-compatible (n = 45) infant heart transplantation recipients ( $\leq$  14 months old, 1996-2006) showed no important differences in pre-transplantation characteristics. In seven patients, donor-specific isohemagglutinin titers were elevated at the time of transplantation but were significantly reduced using intraoperative plasma exchange. Only two of the seven required treatment for AMR (which occurred early post-transplantation, was easily managed and did not recur in follow-up). Occurrence of graft vasculopathy (11%), malignancy (11%) and freedom from severe renal dysfunction were identical in both groups. Survival was identical (74% at 7 years post transplantation). The researchers concluded that ABO-blood group incompatible heart transplantation has excellent outcomes that are indistinguishable from those of the ABO-compatible population and there is no clinical justification for withholding this lifesaving strategy from all infants listed for heart transplantation. Further studies into observed differing responses in the development of donor-specific isohemagglutinins and the implications for graft accommodation are warranted.

## **Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Sydenham's Chorea**

Sigra et al. (2018) conducted a systematic review of published peer reviewed literature which addressed treatment for PANDAS and related disorders. Twelve studies (n = 529) as well as 240 case reports were identified. Treatments evaluated in these studies included IVIG, TPE, antibiotics, cognitive behavior therapy, and tonsillectomy. The authors determined that the studies generally had a high risk of bias and the results were inconclusive. Further rigorous research is needed.

Eighteen patients were entered into a randomized controlled trial (RCT) designed to determine if IVIG or plasma exchange would be superior to prednisone in decreasing the severity of chorea. Mean chorea severity for the entire group was significantly lower at the 1-month follow-up evaluation (overall 48% improvement). Although the between-group differences were not statistically significant, clinical improvements appeared to be more rapid and robust in the IVIG and plasma exchange groups than in the prednisone group (mean chorea severity scores decreased by 72% in the intravenous immunoglobulin group, 50% in the plasma exchange group, and 29% in the prednisone group). According to the authors, larger studies are required to confirm these clinical observations and to determine if these treatments are cost-effective for this disorder (Garvey, 2005).

## **Rheumatoid Arthritis**

In a single institution observational study, Kitagaichi et al. evaluated the efficacy of treatment on 85 individuals with rheumatoid arthritis (RA) using leukocytapheresis (LCAP) and drug therapy initiated between 2006 and 2015. Participants received LCAP once a week for up to 5 weeks. The clinical response was evaluated at the completion of the series and again 4 weeks later using the American College of Rheumatology (ACR) criteria and the 28-joint disease activity score (DAS28) of the European League Against Rheumatism (EULAR). Marked decreases were seen in tender joint count, swollen joint count, and CRP level, and the DAS28-CRP was significantly improved from before to after LCAP. The authors concluded that LCAP is a safe and worthy therapy for individuals with intractable RA where there is drug allergy or other complications. ACR20 response was 61%, and efficacy persisted to 4 weeks after LCAP completion (2016).

Roth (2004) conducted a noninterventional prospective study on 91 patients with RA who qualified for Proserba column apheresis therapy (PCT) per the package insert and completed the 12 prescribed treatments. An initial baseline assessment was performed prior to first treatment and then up to four additional assessments were performed at weeks 9, 16, 20, and 24. Criteria from the ACR (ACR20) were noted in order to assess response rate, and commercial adverse event (AE) reporting was used to record serious/unanticipated AEs. There was a ACR20 (or greater) response rate of 53.8% in these patients with previously refractory RA. The individual criteria showed a much greater improvement than reflected by ACR20; for example, this response included a 52% improvement in joint tenderness, 40% improvement in swelling, 42% improvement in patient's pain, 38% improvement in patient's global response, and 48% improvement in physician's global scores (76% of responders had measured ACR20 by week 16 and 100% by week 24). Some patients stated that they felt improvement began closer to the sixth week. Most responders were concurrently taking biologics or DMARD, e.g., methotrexate and etanercept, despite previously inadequate RA response to those medications. The author concluded that this post-marketing study of PCT used commercially in 59 rheumatology practice settings supports the safety and efficacy of this treatment regime in selected patients with refractory RA and compares favorably with the initial sham controlled clinical trial. PCT is a relatively underutilized choice for the management of active, aggressive RA.

Furst et al. (2000) conducted a double-blind, placebo RCT to determine the efficacy of the ProSORBA Immunoabsorption Column in patients with refractory RA. Ninety nine patients received 12 weekly procedures after being randomized to the active treatment arm or to the sham treatment arm (apheresis only). Evaluations were double-blinded and occurred at baseline and periodically for 24 weeks thereafter. Primary efficacy was assessed at 7 and 8 weeks after the completion of 12 treatments (at trial weeks 19 and 20) using the ACR definition of improvement, and results from the assessments at weeks 19 and 20 were averaged. Analysis of patients who completed all treatments and follow-up indicated that 15 of 36 (41.7%) ProSORBA-treated patients responded compared to 5 of 32 (15.6%) sham-treated patients. Common AEs included joint pain, fatigue, joint swelling, and hypotension. There was no significant increase in AEs in ProSORBA-treated patients compared to sham-treated patients. The authors concluded that immunoabsorption therapy was proven to be a new alternative in patients with severe, refractory disease.

## Cardiovascular Disease

A 2020 ECRI health technology assessment focuses on the effectiveness of LDL apheresis for treating steroid-resistant nephrotic syndrome associated with focal segmental glomerulosclerosis (FSGS.) The conclusion of four small studies reported that LDL apheresis treatment may delay progression to end-stage renal disease and complications associated with chronic kidney disease. Additional studies and long-term follow up would be useful to confirm findings. All studies identified were conducted in Japan and results may not be generalizable to other countries and healthcare systems.

Luirink et al. (2020) performed an observational multicenter cohort study on data from an international registry on the execution and outcomes of lipoprotein apheresis (LA) in children with homozygous familial hypercholesterolemia (hoFH). Their analysis included 50 children aged 0-19 years who were treated at 15 sites in nine countries and who were on medication and LA for hoFH. The median age at diagnosis was 5.0 (3.0-8.0) years, and in 46 (92%) patients, the diagnosis of hoFH or compound heterozygous FH (heFH) was genetically confirmed. The median untreated low-density lipoprotein cholesterol (LDL-C) level was 19.2 (16.2-22.1) mmol/L and the total cholesterol was 22.0 (18.4-24.4) mmol/L for the study participants. On medication, the median LDL-C level was 14.4 (10.8-16.7) mmol/L showing a median reduction of LDL-C on medication of 19.3% (11.6-37.6). The children were started on apheresis on average at 2.8 (1.0-4.7) years after their diagnosis. The frequency of treatment ranged from two times per week to once every three weeks with most patients (n = 21; 43%) being treated weekly or once every two weeks (n = 18; 37%) with most patients (n = 35; 71%) having been treated for more than two years. Their analysis showed that the median LDL-C in patients on LA for longer than 3 months dropped to 4.6 (3.8-7.2) mmol/L with the LDL-C being lower on average the more frequently patients were treated with LA. They reported that 7 (17%) patients reached mean LDL-C levels < 3.5 mmol/L, all of which were treated either once a week (n = 4) or twice a week (n = 3). The authors concluded that the results show that LA may lead to a significant and relevant reduction of LDL-C in children with hoFH and that twice a week LA was significantly more effective in lowering mean LDL-C. They noted that the study had several limitations including the potential for variability in the data being entered and that the results might not be representative of the entire population of children with hoFH since the registry was not open to all sites treating all children with hoFH around the world. The authors recommend further studies with long-term follow-up data of the effect of LA on CVD or surrogate markers for CVD.

Khan et al. (2017) conducted a single-blinded RCT to determine the clinical impact of lipoprotein apheresis in 20 patients with refractory angina and raised lipoprotein(a) > 500 mg/L. Participants received 3 months of blinded weekly lipoprotein apheresis or sham, followed by crossover. The primary endpoint was change in quantitative myocardial perfusion reserve (MPR). Secondary endpoints included measures of atheroma burden, exercise capacity, symptoms, and quality of life. MPR increased following apheresis compared with sham, yielding a net treatment increase of 0.63. All secondary endpoints showed improvements as well. The researchers concluded that lipoprotein apheresis may represent an effective novel treatment for patients with refractory angina and raised lipoprotein(a). They state that a larger study in these patients incorporating the impact of apheresis on major cardiovascular AEs would help to validate the findings.

Low levels of high-density lipoprotein (HDL) are associated with increased risk of cardiovascular disease. Researchers theorize that plasma selective delipidation converts alpha-HDL to pre-beta-like HDL, the most effective form of HDL for lipid removal from arterial plaques. However, there is a paucity of clinical evidence regarding HDL delipidation for various cardiac disease indications, including acute coronary syndrome (ACS). A search of the peer-reviewed medical literature identified one placebo-controlled RCT (n = 28) (Waksman et al., 2010). This study sought to determine whether serial autologous infusions of selective HDL delipidated plasma are feasible and well tolerated in patients with ACS. Patients undergoing cardiac catheterization were randomized to either seven weekly HDL selective delipidated or control plasma apheresis/ reinfusions. Patients underwent intravascular ultrasound (IVUS) evaluation of the target vessel. All reinfusion sessions were tolerated well by all patients. The levels of prebeta-like HDL and alphaHDL in the delipidated plasma converted from 5.6% to 79.1% and 92.8% to 20.9%,

respectively. The IVUS data demonstrated a numeric and non-significant trend toward regression in the total atheroma volume in the delipidated group compared with an increase of total atheroma volume in the control group. Study results demonstrated that serial autologous infusions of selective HDL delipidated plasma is clinically feasible and well tolerated. Study limitations included small study population and lack of appropriate blinding methods. The study may not have been sufficiently powered to detect differences between treatment and controls. Additional well-designed studies are necessary to determine the ability of HDL delipidation and plasma reinfusion to improve patient-relevant clinical outcomes, such as the reduction of cardiovascular events and increased overall survival.

A prospective, multicenter, international, two-arm matched-pair cohort study known as MultiSELEct is in progress, evaluating the clinical benefit of lipoprotein apheresis on cardiovascular outcomes. For more information, refer to [www.clinicaltrials.gov](http://www.clinicaltrials.gov) and review Identifier NCT02791802. (Accessed August 9, 2022).

## Light Chain Nephropathy

In a multicenter retrospective study from 10 plasmapheresis centers in Turkey, Kalpakci et al (2021) observed that Therapeutic Plasma Exchange (TPE) reduced all biochemical markers related to cast nephropathy (CN) in patients with multiple myeloma (MM) when TPE was performed for up to seven days until improvement was seen in patient's symptoms and laboratory findings. A mean Mean: 3.3 (median: 3) sessions of TPE were performed in newly diagnosed MM, mean: 4 (median: 4.5) sessions of TPE were performed in relapsed refractory disease, and 22 patients received concomitant chemotherapy containing bortezomib. According to the authors, the overall response rate was 83.6% (n = 51) with statistically significant differences observed in serum levels of all clinically relevant biomarkers before and after treatment. The authors stated that TPE also contributed to the clinical improvement in 40 of 50 multiple myeloma patients with CN. The incidence of side effects associated with TPE was reported by the authors to affect four patients (6.6%), with no severe side effects that required termination of the procedure. These results were noted one week after TPE was added to standard medical treatment. The authors noted that the main limitations of their study were the small sample size and the absence of a comparative control group,

Premuzic et al. examined whether plasmapheresis in combination with chemotherapy could significantly remove free light chains (FLCs) in multiple myeloma (MM) patients with acute kidney injury (AKI), ultimately improving renal recovery and patient survival in a single center study. During the study period, 29 patients with MM and AKI were treated with two different therapy modalities (plasmapheresis with chemotherapy or bortezomib). At the end of treatment, a significant decrease of FLCs was present in the group treated with plasmapheresis compared to the bortezomib group. While overall survival was similar between groups, there was a significantly higher decrease of FLCs and longer survival in patients treated with  $\geq 3$  plasmapheresis sessions than in patients treated with two sessions. The authors concluded that plasmapheresis therapy still remains a useful and effective method in the treatment of AKI in MM patients. Plasmapheresis significantly reduces FLCs compared to bortezomib, especially with higher number of plasma exchange sessions, but it must be combined with other chemotherapy agents in order to prolong renal recovery and therefore patient survival (2018).

Yu et al. (2015) conducted a meta-analysis to quantitatively evaluate the clinical efficacy of chemotherapy with or without plasmapheresis in the treatment of MM patients with renal failure. Three RCTs were selected and analyzed. A total of 63 patients received chemotherapy only and 84 patients were given both chemotherapy and plasmapheresis. No difference was observed in 6-month survival rate between plasmapheresis and control group (75% vs. 66.7%). The 6-month dialysis-dependent ratio was significantly lower in patients treated with both chemotherapy and plasmapheresis than chemotherapy alone (15.6% vs. 37.2%). The authors concluded that plasmapheresis used as an adjunct to chemotherapy had a benefit in the management of dialysis-dependent MM patients with renal failure.

A systematic review covering 56 articles regarding survival benefits, recovery, and improvement in renal function after extracorporeal removal of sFLCs did not suggest a benefit of plasmapheresis independent of chemotherapy for MM patients with acute renal injury (Gupta et al., 2010).

## Inflammatory Bowel Disease

A retrospective observational study was completed by Fukuchi et al. (2022) to examine the long-term maintenance rate after inducing remission by intensive granulocyte/monocyte adsorptive apheresis (GMA) without use of corticosteroids (CS) and GMA re-treatment efficacy in the same patients upon relapse with ulcerative colitis. Patients who achieved clinical remission and mucosal healing (MH) by first-time intensive GMA (first GMA) without CS were enrolled. The cumulative non-relapse survival



rate up to week 156 was calculated. Patients with relapse during the maintenance period underwent second-time intensive GMA (second GMA) without CS. Clinical remission and MH rates following second GMA were compared to those following first GMA in the same patients. Of the 84 patients enrolled, 78 were followed until week 156 and 34 demonstrated relapse. The cumulative non-relapse survival rate by week 156 was 56.4%. Clinical remission and MH rates after second GMA did not differ from those after first GMA in the same patients (week 6: clinical remission, 100% vs. 88.4%,  $p = 0.134$ ; MH, 100% vs. 84.8%,  $p = 0.074$ ). The authors concluded for the goal of MH in UC patients, intensive GMA prior to use of CS and biologics can be a suitable choice. Such cases generally have a favorable clinical prognosis, including a sufficient rate of clinical remission maintenance, as well as superior re-induction rate of clinical and endoscopic remission by GMA re-treatment even when disease relapse occurs.

In a systematic review and meta-analysis on the role of granulocyte and monocyte apheresis (GMA) in the induction and maintenance of clinical remission in ulcerative colitis (UC), Kiss, et al. (2021) analyzed 11 studies that included a total of 589 patients. The studies consisted of 11 RCTs with one study with minimization. Eight of the studies reported on patients with active UC and three contained data on patients with UC who were in clinical remission. In the studies on patients with active UC, 350 patients received GMA and 248 were in control groups. With regard to the three studies reporting on patients with UC who were in clinical remission, there were 71 participants, of which, 36 received GMA and 35 were in the control groups. Risk of bias was assessed as high risk for three of the studies due to the unblinded design of the studies, four studies were assessed as high risk due to the lack of a description of the blinding process and two others were assessed as high risk of bias for other biases. The authors noted that their results were limited by the relatively low number of patients and the heterogenous reporting of adverse events. The study was also limited by the heterogeneity of the study designs such as the treatments rendered, the length of the studies, and the number of participants. The authors concluded that GMA appears to be more effective as an adjunctive treatment in inducing and maintaining remission in patients with UC than conventional therapy alone (low certainty). The authors recommend further RCTs to justify the role of GMA for inducing remission in patients with UC.

A large-scale, prospective, observational study was performed by Yokoyama et al. (2014) which enrolled patients from 116 medical facilities in Japan with active ulcerative colitis (UC) treated with LCAP. Out of 847 patients, 623 were available for efficacy analysis. 80.3% of the patients had moderate to severe disease activity, and 67.6% were steroid refractory. Concomitant medications, 5-aminosalicylic acids, corticosteroids, and thiopurines were administered to 94.8%, 63.8%, and 32.8% of the patients, respectively. In addition, infliximab and tacrolimus were concomitantly used in 5.8% and 12.3%, respectively. Intensive LCAP ( $\geq 4$  sessions within the first 2 weeks) was used in  $> 70\%$  of the patients. AEs were seen in 10.3%, which were severe in only five patients. Any concomitant medications did not increase the incidence of AEs. The authors concluded that that LCAP, including intensive procedure, is a safe and effective therapeutic option for active UC. However, this study did not translate research data into clinical guidelines that can be used to improve physician decision-making and patient care.

## Clinical Practice Guidelines

### *American College of Rheumatology (ACR)*

In their 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis the ACR focused their guidance on the pharmacologic management of rheumatoid arthritis. Although they initially intended to include nonpharmacologic treatment approaches in this guideline, the ACR stated that the use of vaccines and nonpharmacologic treatment approaches will be included in future ACR treatment guideline publications.

### *American Society for Apheresis (ASFA)*

The ASFA (Padmanabhan et al., 2019) has reviewed therapeutic apheresis outcomes and published practice guidelines. The guidelines included analysis based on the quality of the evidence as well as the strength of recommendation derived from the evidence. ASFA categorizes disorders as noted below:

- Category I: Disorders for which apheresis is accepted as first-line therapy, either as a primary standalone treatment or in conjunction with other modes of treatment.
- Category II: Disorders for which apheresis is accepted as second-line therapy, either as a standalone treatment or in conjunction with other modes of treatment.
- Category III: Optimum role of apheresis therapy is not established. Decision making should be individualized.
- Category IV: Disorders in which published evidence demonstrates or suggests apheresis to be ineffective or harmful. IRB approval is desirable if apheresis treatment is undertaken in these circumstances.

ASFA recognized that categories alone are difficult to translate into clinical practice. Thus, they adopted a system to assign recommendation grades for therapeutic apheresis to enhance the clinical value of ASFA categories. The grading recommendations are adopted from Guyatt et al., 2008, Szczepiorkowski et al., 2010, Schwartz et al., 2016, and Padmanabhan et al., 2019:

- Grade 1A: Strong recommendation, high-quality evidence.
- Grade 1B: Strong recommendation, moderate quality evidence.
- Grade 1C: Strong recommendation, low-quality or very low-quality evidence.
- Grade 2A: Weak recommendation, high quality evidence.
- Grade 2B: Weak recommendation, moderate quality evidence.
- Grade 2C: Weak recommendation, low-quality or very low-quality evidence.

Regarding sickle cell disease, ASFA states:

- Red blood cell (RBC) exchange is an option for patients with acute stroke, severe acute chest syndrome (ACS), or other complications including but not limited to multiorgan failure.
- RBC exchange is also recommended as a prophylaxis for primary or secondary stroke.
- Studies have shown automated RBC exchange results in a more efficient removal/replacement of HbS RBCs than manual exchange or simple transfusions.
- Long-term RBC exchange has the advantage of preventing or markedly reducing transfusional iron accumulation (Padmanabhan et al., 2019).

### ***American Society of Hematology (ASH)***

The ASH published a clinical guideline for the prevention, diagnosis, and treatment of cerebrovascular disease in children and adults with sickle cell disease that includes the following as strong recommendations (DeBaun et al. 2020):

- For children with HbSS or HbS $\beta$ 0 thalassemia (ages 2-16 years), the panel recommends:
  - Annual Transcranial Doppler (TCD) screening (strong recommendation).
  - Regular blood transfusions for at least a year (vs no transfusion) with the goal of keeping maximum HbS levels below 30% and maintaining hemoglobin levels .9.0 g/dL to reduce the risk of stroke for children with abnormal TCD velocities who live in a high-income setting where regular blood transfusion therapy, typically every 3-4 weeks, is feasible (strong recommendation).
  - Blood transfusion goals for secondary stroke prevention of increasing the hemoglobin above 9 g/dL at all times and maintaining the HbS level at 30% of total hemoglobin until the time of the next transfusion, if the child has a history of prior ischemic stroke.
- For children or adults with SCD and acute neurological deficits, including transient ischemic attack (TIA), the ASH guideline panel recommends prompt blood transfusion given immediately upon recognition of symptoms within 2 hours of acute neurological symptom presentation. The type of transfusion (simple, modified exchange, or apheresis) is dependent on individual patient factors and local transfusion resources.

The ASH guideline also includes the following conditional recommendations:

- For children who have compound heterozygous SCD other than HbSC and have evidence of hemolysis in the same range as those with HbSS, the ASH guideline panel suggests:
  - TCD screening.
  - Regular blood transfusions for at least a year (vs. no transfusion) with the goal of keeping maximum HbS levels below 30% to reduce the risk of stroke if the child has an abnormal TCD velocity, and lives in a high-income setting where regular blood transfusion therapy is feasible.
- For children with SCD (ages 2-16 years) and abnormal TCD results who have been receiving transfusion therapy for at least 1 year and are interested in stopping transfusion, according to the clinical trial risk stratification with an MRI and magnetic resonance angiography (MRA) of the brain, the ASH guideline panel suggests that hydroxyurea treatment at the maximum tolerated dose can be considered to substitute for regular blood transfusions.
- For children (ages 2-16 years) with HbSS, HbS $\beta$ 0 thalassemia, or compound heterozygous SCD who have abnormal TCD screening and live in low-middle-income settings where regular blood transfusion therapy and chelation therapy are not available or affordable, the ASH guideline panel suggests hydroxyurea therapy with at least 20 mg/kg per day at a fixed dose or the maximum tolerated dose.
- For children or adults with SCD and acute neurological deficits including TIA, the ASH guideline panel suggests exchange transfusion vs. simple transfusion. When exchange transfusion is not available within 2 hours of presentation for medical



care and hemoglobin is #8.5 g/dL, simple transfusion can be performed to avoid delays in treatment while a manual exchange transfusion or an automated apheresis is planned.

- For adults and children with SCD, moyamoya syndrome, and a history of stroke or TIA, the ASH guideline panel suggests evaluation for revascularization surgery in addition to regular blood transfusion.
- For all patients, the administration of tissue plasminogen activator (tPA) should not delay prompt simple or exchange blood transfusion therapy for adults with SCD presenting with symptoms of acute ischemic stroke who are being evaluated for IV tPA [age ≥ 18 years, no hemorrhage on computed tomography (CT) scan, within 4.5 hours of onset of symptoms/signs and without contraindications for thrombolysis].

The ASH also published guidelines for transfusion support for patients with SCD which includes the following suggestions regarding transfusion and transfusion modalities in patients with SCD who require chronic therapy (Chou et al., 2020):

- The use of automated red cell exchange (RCE) over simple transfusion or manual RCE:
  - In patients with SCD (all genotypes) receiving chronic transfusions.
  - In patients with SCD and severe acute chest syndrome.
  - In patients with SCD and moderate acute chest syndrome.
- Either RCE with isovolemic hemodilution (IHD-RCE) or conventional RCE in patients with SCD (all genotypes) receiving chronic transfusions.
- Either prophylactic transfusion at regular intervals or standard care (transfusion when clinically indicated for a complication or hemoglobin lower than baseline) for pregnant patients with SCD (all genotypes).
- Preoperative transfusion over no preoperative transfusion in patients with SCD undergoing surgeries requiring general anesthesia and lasting more than 1 hour.
- Iron overload screening by MRI (MRI; R2, T2\*, or R2\*) for liver iron content every 1 to 2 years compared with serial monitoring of ferritin levels alone in patients with SCD (all genotypes) receiving chronic transfusion therapy.
- Not adding routine iron overload screening by T2\* MRI for cardiac iron content compared with serial monitoring of ferritin levels alone in patients with SCD (all genotypes) receiving chronic transfusion therapy.

### ***National Comprehensive Cancer Network (NCCN)***

Guidelines on acute myeloid leukemia indicate that leukapheresis is not recommended in the routine management of patients with a high WBC in acute promyelocytic leukemia (APL) because of the difference in leukemia biology. However, in life threatening cases with leukostasis that is not responsive to other modalities, leukapheresis can be considered with caution (2022).

The NCCN Clinical Practice Guideline for Multiple Myeloma indicates that plasmapheresis should be used as an adjunctive therapy for symptomatic hyperviscosity. The guideline also notes that supportive management of renal disease in multiple myeloma includes plasmapheresis for the mechanical removal of Free Light Chains (FLCs) with a goal of removal of 50% as a category 2B recommendation (2022).

### ***National Heart, Lung, and Blood Institute (NHLBI)***

The NHLBI published a clinical guideline for the management of SCD that includes the following recommendations relative to therapeutic apheresis (2014):

- In children with Sick Cell Anemia (SCA), screen annually with Transcranial Doppler (TCD) screening according to methods employed in the Stroke Prevention Trial in Sick Cell Anemia (STOP) studies, beginning at age 2 and continuing until at least age 16.
- In children with conditional (170-199 cm/sec) or elevated (> 200 cm/sec) TCD results, refer to a specialist with expertise in chronic transfusion therapy aimed at preventing stroke.
- In children and adults with SCD with confirmed acute hepatic syndrome (AHS) or severe acute intrahepatic cholestasis (AIC), perform simple or exchange transfusion.
- In all persons with SCD, perform urgent exchange transfusion – with consultation from hematology, critical care, and/or apheresis specialists – when there is rapid progression of ACS as manifested by oxygen saturation below 90 percent despite supplemental oxygen, increasing respiratory distress, progressive pulmonary infiltrates, and/or decline in hemoglobin concentration despite simple transfusion.
- In consultation with a sickle cell expert, perform exchange transfusion in people with SCD who develop acute stroke confirmed by neuroimaging.

- Initiate prompt evaluation, including neurologic consultation and neuroimaging studies, in people with SCD who have mild, subtle, or recent history of signs or symptoms consistent with transient ischemic attack.
- In children and adults who have had a stroke, initiate a program of monthly simple or exchange transfusions.
- In people with SCD and multi-symptom organ failure (MSOF), immediately initiate either simple or exchange transfusion in consultation with a sickle cell expert or hematologist.
- In adults and children with SCA, transfuse red blood cells (RBCs) to bring the hemoglobin level to 10 g/dL prior to undergoing a surgical procedure involving general anesthesia.
- In adults and children with Hemoglobin SC disease (HbSC) or Hemoglobin SB+ (beta) thalassemia (HbSB+-thalassemia), consult a sickle cell expert to determine if full or partial exchange transfusion is indicated before a surgical procedure involving general anesthesia.
- Administer iron chelation therapy, in consultation with a hematologist, to patients with SCD and with documented transfusion-acquired iron overload.

### ***National Institute of Neurological Disorders and Stroke (NINDS)***

The Neuromyelitis Optica (NMO) information page states that relapses and attacks of NMO (also known as Devic Syndrome) are often treated with corticosteroids and plasma exchange (National Institutes of Health, July 2022).

### ***National Institute for Health and Care Excellence (NICE)***

In the clinical pathway for managing familial hypercholesterolemia (FH), NICE (2021) made the following recommendations regarding clinical indications for low density lipoprotein (LDL) apheresis:

- Lipid-modifying drug therapy be considered before LDL apheresis in patients under 16 years of age;
- LDL apheresis should be considered for adults and children/young people with homozygous FH depending on factors such as the person's response to lipid-modifying drug therapy and the presence of coronary artery disease;
- LDL apheresis should be considered for people with heterozygous FH in exceptional circumstances, such as when there is progressive, symptomatic heart disease that does not respond to maximal tolerated lipid-modifying drug therapy and optimal medical and surgical therapy.

NICE clinical guidelines on the management of MS in adults do not address any type of therapeutic apheresis (2022).

NICE also recommended that Extracorporeal Photopheresis should not be used outside the context of research for Crohn's disease for both adults and children (2009).

## **U.S. Food and Drug Administration (FDA)**

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

Devices for therapeutic apheresis are regulated by the FDA as Class II or III devices depending on whether they rely on centrifugation or filtration of blood. Devices that separate blood cells from plasma by filtration are Class III devices that are subject to the most extensive regulations enforced by the FDA.

For additional information, search product code LKN (separator, automated, blood cell and plasma, therapeutic) at the following website: <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmnm.cfm>. (Accessed August 9, 2022)

The FDA has granted premarket approval (PMA) to one Extracorporeal Photopheresis (ECP) device, the UVAR Photopheresis System (Therakos, Inc., Exton, PA, USA). This system is currently only approved for the palliative treatment of skin manifestations resulting from cutaneous T-cell lymphoma (CTCL), which are unresponsive to other treatments. Therakos now markets a second generation of the system under the name UVAR XTS. The UVAR XTS system utilizes the photoactive drug, UVADEX (8-methoxsalen), also manufactured by Therakos and is approved by FDA for the same indication. Additional information is available at the following website:

[https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?start\\_search=1&applicant=&tradename=&productcode=&pmanumber=P860003&supplementnumber=&advisorycommittee=&docketnumber=&supplementtype=&expeditedreview=&vdproducts=off&combinationproducts=off&decisiondatefrom=&decisiondateto=&noticedatefrom=&noticedateto=&PAGENUM=50](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?start_search=1&applicant=&tradename=&productcode=&pmanumber=P860003&supplementnumber=&advisorycommittee=&docketnumber=&supplementtype=&expeditedreview=&vdproducts=off&combinationproducts=off&decisiondatefrom=&decisiondateto=&noticedatefrom=&noticedateto=&PAGENUM=50). (Accessed August 9, 2022)

UVADEX was granted Orphan Drug Status “for use in conjunction with the UVAR photopheresis [system] to treat diffuse systemic sclerosis” in June 1993 and “for use in conjunction with the UVAR photopheresis system to treat graft versus host disease (GVHD)” in October 1998. In addition, UVADEX was granted Orphan Drug Status “for the prevention of acute rejection of cardiac allografts” in May 1994. Additional information is available at the following website: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2013/020969s006lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020969s006lbl.pdf). (Accessed August 9, 2022)

## References

- Campise M, Favi E, Messa P. Clinical outcomes of prophylactic and therapeutic plasmapheresis in adult deceased-donor kidney transplant recipients with primary focal segmental glomerulosclerosis. *Exp Clin Transplant*. 2019 Aug;17(4):461-469.
- Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. *Blood Adv* (2020) 4 (2): 327-355.
- DeBaun MR, Jordan LC, King AA, et al. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. *Blood Adv* (2020) 4 (8): 1554-1588.
- Dipchand AI, Pollock BarZiv SM, Manlihot C, et al. Equivalent outcomes for pediatric heart transplantation recipients: ABO-blood group incompatible versus ABO-compatible. *Am J Transplant*. 2010 Feb;10(2):389-97.
- ECRI Institute Health Technology Assessment. Low-density lipoprotein apheresis for treating hyperlipidemia in patients with nephrotic syndrome. March 2020.
- Estcourt LJ, Fortin PM, Hopewell S, et al. Regular long-term red blood cell transfusions for managing chronic chest complications in sickle cell disease. *Cochrane Database Syst Rev*. 2016;(5):CD008360; updated 2019.
- Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. *Arthritis Care Res (Hoboken)*. 2021 Jul;73(7):924-939.
- Fukuchi T, Kawashima K, Koga H, et al. Induction of mucosal healing by intensive granulocyte/monocyte adsorptive apheresis (GMA) without use of corticosteroids in patients with ulcerative colitis: long-term remission maintenance after induction by GMA and efficacy of GMA re-treatment upon relapse. *J Clin Biochem Nutr*. 2022 Mar;70(2):197-204.
- Furst D, Felson D, Thoren G, et al. Immunoabsorption for the treatment of rheumatoid arthritis: Final results of a randomized trial. *Prosorba Trial Investigators. Ther Apher*. 2000 Oct;4(5):363-73. Erratum in: *Ther Apher* 2002 Feb;6(1):99.
- Garvey MA, Snider LA, Leitman SF, et al. Treatment of Sydenham's chorea with intravenous immunoglobulin, plasma exchange, or prednisone. *J Child Neurol*. 2005 May;20(5):424-9.
- Gupta D., Bachegowda L., Phadke G., et al. Role of plasmapheresis in the management of myeloma kidney: a systematic review. *Hemodial Int* 2010; 14: pp. 355-363.
- Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ Clin Res Ed* 2008; 336:924-926.
- Hequet O, Boisson C, Joly P, et al. Priming with red blood cells allows red blood cell exchange for sickle cell disease in low-weight children. *Front Med (Lausanne)*. 2021 Dec 22;8:743483.
- Hulbert ML, Scothorn DJ, Panepinto JA, et al. Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: a retrospective cohort study of 137 children with sickle cell anemia. *J Pediatr*. 2006 Nov;149(5):710-2.
- Issitt R, Booth J, Crook R, et al. Intraoperative anti-A/B immunoabsorption is associated with significantly reduced blood product utilization with similar outcomes in pediatric ABO-incompatible heart transplantation. *J Heart Lung Transplant*. 2021 Nov;40(11):1433-1442.
- Issitt RW, Crook RM, Cross NT, et al. Incompatible ABO-plasma exchange and its impact on patient selection in paediatric cardiac transplantation. *Perfusion*. 2012 Nov;27(6):480-5.
- Kalpakci Y, Hacibekiroglu T, Darcin T, et al. Efficacy and safety of plasmapheresis in symptomatic hyperviscosity and cast nephropathy: A Multicenter Experience in Turkey. *Transfus Apher Sci*. 2021 Oct;60(5):103244.
- Khan TZ, Hsu LY, Arai AE, et al. Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial. *Eur Heart J*. 2017 May 21;38(20):1561-1569.

Kiss S, Németh D, Hegyi P, et al. Alizadeh H. Granulocyte and monocyte apheresis as an adjunctive therapy to induce and maintain clinical remission in ulcerative colitis: a systematic review and meta-analysis. *BMJ Open*. 2021 May 19;11(5):e042374.

Kitagaichi M, Kusaoi M, Tsukahara T, et al. Safety and efficacy of the leukocytapheresis procedure in eighty-five patients with rheumatoid arthritis. *Transfus Apher Sci*. 2016 Oct;55(2):225-232.

Luirink IK, Hutten BA, Greber-Platzer S, et al. Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry. *Atherosclerosis*. 2020 Apr;299:24-31.

Martí-Carvajal AJ, Martí-Amarista CE. Interventions for treating intrahepatic cholestasis in people with sickle cell disease. *Cochrane Database of Systematic Reviews* 2020, Issue 6. Art. No.: CD010985.

Meng HL, Jin XB, Li XT, et al. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients. *Chin Med J (Engl)*. 2009 Feb 20;122(4):420-6.

Montgomery RA, Lonze BE, Jackson AM. Using donor exchange paradigms with desensitization to enhance transplant rates among highly sensitized patients. *Curr Opin Organ Transplant*. 2011b Aug;16(4):439-43.

Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. *N Engl J Med*. 2011a Jul 28;365(4):318-26.

Mukherjee S, Sahu A, Ray GK, et al. Comparative evaluation of efficacy and safety of automated versus manual red cell exchange in sickle cell disease: a systematic review and meta-analysis. *Vox Sang*. 2022 Aug;117(8):989-1000.

National Cancer Institute. NCI Dictionary of Cancer Terms. 21.09d; September 27, 2021: Bethesda, MD.

National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Acute Myeloid Leukemia. v2.2022. June 14, 2022.

National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Multiple Myeloma. v5.2022. March 9, 2022.

National Heart, Lung, and Blood Institute (NHLBI). Evidence-Based Management of Sickle Cell Disease. Expert Panel Report 2014. U.S. Department of Health and Human Services; National Institutes of Health.

National Institute for Health and Care Excellence (NICE). Extracorporeal Photopheresis for Crohn's Disease. Interventional procedures guidance [IPG288]. February 2009. Accessed August 9, 2022.

National Institute for Health and Care Excellence (NICE). Managing familial hypercholesterolaemia. April 2021. Accessed August 9, 2022.

National Institute for Health and Care Excellence (NICE). Multiple sclerosis in adults: management. Clinical guideline [NG220]. June 2022. Accessed August 9, 2022.

National Institutes of Health (NIH), National Institute for Neurological Disorders and Stroke (NINDS). Neuromyelitis Optica Information Page. Bethesda, MD: NIH; updated July 2022. Accessed August 9, 2022.

Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. *J Clin Apher*. 2019 Jun;34(3):171-354.

Premuzic V, Batinic J, Roncevic P, et al. Role of plasmapheresis in the management of acute kidney injury in patients with multiple myeloma: Should we abandon it? *Ther Apher Dial*. 2018 Feb;22(1):79-86.

Roth S. Effects of ProSORBA column apheresis in patients with chronic refractory rheumatoid arthritis. *J Rheumatol*. 2004 Nov;31(11):2131-5.

Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American Society for Apheresis: The Seventh Special Issue. *J Clin Apher*. 2016 Jun;31(3):149-62.

Sigra S, Hesselmark E, Bejerot S. Treatment of PANDAS and PANS: a systematic review. *Neurosci Biobehav Rev*. 2018 Mar; 86:51-65.

Turner JM, Kaplan JB, Cohen HW, et al. Exchange versus simple transfusion for acute chest syndrome in sickle cell anemia adults. *Transfusion* 2009; 49:863-868.

Velasquez MP, Mariscalco MM, Goldstein SL, et al. Erythrocytapheresis in children with sickle cell disease and acute chest syndrome. *Pediatric Blood Cancer* 2009; 53:1060-1063.

Venkateswaran L, Teruya J, Bustillos C, et al. Red cell exchange does not appear to increase the rate of allo- and auto-immunization in chronically transfused children with sickle cell disease. *Pediatr Blood Cancer*. 2011 Aug;57(2):294-6.

Wade J, Yee MEM, Easley KA, et al. Procedural adverse events in pediatric patients with sickle cell disease undergoing chronic automated red cell exchange. *Transfusion*. 2022 Mar;62(3):584-593.

Wahl SK, Garcia A, Hagar W, et al. Lower alloimmunization rates in pediatric sickle cell patients on chronic Erythrocytapheresis compared to chronic simple transfusions. *Transfusion*. 2012 Dec;52(12):2671-6.

Waksman R, Torguson R, Kent KM et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. *J Am Coll Cardiol*. 2010 Jun 15;55(24):2727-2735.

Yokoyama Y, Matsuoka K, Kobayashi T, et al. A large-scale, prospective, observational study of leukocytapheresis for ulcerative colitis: treatment outcomes of 847 patients in clinical practice. *J Crohns Colitis*. 2014 Sep;8(9):981-91.

Yu X, Gan L, Wang Z, et al. Chemotherapy with or without plasmapheresis in acute renal failure due to multiple myeloma: a meta-analysis. *Int J Clin Pharmacol Ther*. 2015 May;53(5):391-7.

Yuan XP, Wang CX, Gao W, et al. Kidney transplant in highly sensitized patients after desensitization with plasmapheresis and low-dose intravenous immunoglobulin. *Exp Clin Transplant*. 2010 Jun;8(2):130-5.

## Policy History/Revision Information

Date	Summary of Changes
12/01/2023	<p><b>Application</b> <b>Indiana</b></p> <ul style="list-style-type: none"> <li>Removed reference link to state-specific policy version</li> </ul>
03/01/2023	<p><b>Related Policies</b></p> <ul style="list-style-type: none"> <li>Removed reference link to the Medical Policy titled <i>Spinal Fusion Enhancement Products</i></li> </ul> <p><b>Coverage Rationale</b></p> <ul style="list-style-type: none"> <li>Revised list of conditions/diagnoses for which therapeutic apheresis is <b>unproven and not medically necessary</b>; replaced “<i>PANDAS</i>; Sydenham’s chorea, severe” with “Sydenham’s chorea, severe”</li> </ul> <p><b>Definitions</b></p> <ul style="list-style-type: none"> <li>Added definition of: <ul style="list-style-type: none"> <li>Photopheresis</li> <li>Plasma Exchange</li> <li>Therapeutic Apheresis</li> </ul> </li> </ul> <p><b>Supporting Information</b></p> <ul style="list-style-type: none"> <li>Updated <i>Description of Services, Clinical Evidence, FDA, and References</i> sections to reflect the most current information</li> <li>Archived previous policy version CS004.N</li> </ul>

## Instructions for Use

This Medical Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the federal, state or contractual requirements for benefit plan coverage must be referenced as the terms of the federal, state or contractual requirements for benefit plan coverage may differ from the standard benefit plan. In the event of a conflict, the federal, state or contractual requirements for benefit plan coverage govern. Before using this policy, please check the federal, state or contractual requirements for benefit plan coverage. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Policy is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare may also use tools developed by third parties, such as the InterQual® criteria, to assist us in administering health benefits. The UnitedHealthcare Medical Policies are intended to be used in connection with the independent

professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.